A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
Condition: Melanoma Stage III Interventions: Drug: Pembrolizumab; Drug: Lenvatinib Sponsors: Melanoma Institute Australia; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials